Details for Patent: 8,993,583
✉ Email this page to a colleague
Title: | 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
Abstract: | Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. Exemplary compounds disclosed in this application are shown below: ##STR00001## |
Inventor(s): | Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA) |
Assignee: | ICOS Corporation (Foster City, CA) |
Filing Date: | Oct 08, 2013 |
Application Number: | 14/049,154 |
Claims: | 1. A pharmaceutically acceptable salt of a compound selected from the group consisting of ##STR00184## wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride salt, hydrobromide salt, hydroiodide salt and phosphate salt. 2. A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 1 and at least one pharmaceutically acceptable excipient. 3. The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 4. The pharmaceutical composition of claim 2, wherein the compound is the S-enantiomer. 5. The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 6. A kit comprising the pharmaceutically acceptable salt according to claim 1. 7. The kit according to claim 6, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 8. The kit according to claim 6 wherein the compound is the S-enantiomer. 9. The kit according to claim 8, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 10. The pharmaceutically acceptable salt according to claim 1, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 11. The pharmaceutically acceptable salt according to claim 1, wherein the compound is the S-enantiomer. 12. The pharmaceutically acceptable salt according to claim 1, wherein the compound is ##STR00185## and the pharmaceutically acceptable salt is the hydrochloride salt. 13. The pharmaceutically acceptable salt according to claim 1, wherein the compound is ##STR00186## and the pharmaceutically acceptable salt is the hydrochloride salt. |